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To the Editor:  
The prevalence of atrial fibrillation (AF) rises with advancing age reaching almost 10% in 
octogenarians
1
. Progress in medicine leads physicians to prescribe more Vitamin K 
antagonists (VKA) in octogenarians according to Evidence-Based Clinical Practice 
Guidelines
2,3,4
. The guidelines are however unclear regarding the need for heparin bridging 
therapy (HBT) at the initiation of VKA in patient without indication for immediate 
cardioversion. Indeed, the American College of Cardiology (ACC), the American Heart 
Association (AHA) and the European Society of Cardiology (ESC)
2,4
 give no specific 
recommendation. The American College of Chest Physicians (ACCP)
3
 specifies that “stable 
patients with AF can be anticoagulated on an outpatient basis with VKAs alone” but adds that 
“For particularly worrisome patients, physicians may be more comfortable with a 
heparin/warfarin bridging regimen”. Who are the “particularly worrisome” patients? Should 
HBT be prescribed in octogenarians with high risk for thromboembolism and low risk for 
bleeding, as assessed by scores?  
This article reports the results of an ancillary study from a pharmacokinetic and 
pharmacodynamic study on fluindione in French octogenarian inpatients. This ancillary study 
aimed to characterize the rate of HBT use in octogenarians starting AF-related anticoagulation 
during an acute care stay and to describe the thrombotic and bleeding events occurring during 
this stay. 
METHOD: 
The multicenter, prospective PREPA study was conducted between September 2005 and 
September 2007 in 6 medical and 1 surgical (cardiac) acute-care units at 3 French university-
affiliated hospitals. The objective of the PREPA study was to model the pharmacokinetic and 
pharmacodynamic components of the response to fluindione in octogenarians inpatients 
starting fluindione (VKA-naive patients or after a 15-day wash-out) regardless of indication 
(AF,venous thrombo-embolism, valvular prosthesis). Consecutive patients were included and 
physicians managed drugs according to routine clinical practice, without any algorithm. 
Therefore this study reflects real life practice of HBT. For this ancillary study, analyses were 
restricted to patients who were newly prescribed VKA for AF. Exclusion criteria were: 
fluindione absolute contraindications, contraindicated comedication, inability to give 
informed consent, inclusion in another trial of therapeutic evaluation and expected length of 
stay <3 days. Patients were followed until their discharge from the study unit or during the 
subsequent 30 days after the inclusion. Causes for premature withdrawal from the study were 
death, consent withdrawal or prescription of Vitamin K and/or Prothrombin complex 
concentrates. All bleeding and embolic events occurring during the follow-up were collected. 
Bleeding was considered severe if it required stopping VKA and/or additional procedure 
and/or treatment. Scores for thrombo-embolism and bleeding risks, as described in the 2010 
ESC guidelines
4
, were retrospectively assessed in patients with bleeding events. 
RESULTS  
Among the 132 included patients, 69 patients were newly prescribed VKA for AF. These 
patients were mostly females (N=44, 64%) and had a mean age of 86 ± 4 years. 20 (29%) 
patients were in post-operative care after cardiac surgery. The mean Charlson comorbidity 
index was 6.7 ± 2.4 and the patients had 8 ± 3 daily comedications at inclusion. Heparin or its 
derivatives were prescribed as a bridge therapy in 59 (85.5%) of these patients. None had an 
indication of cardioversion. General attrition rate during PREPA study was high, with a short 
length of stay: 49.2% of the included patients remained in the study at D7, 56.2% in the 
subgroup of AF-patients new to VKA. No thrombotic event occurred in the 69 VKA-naive AF 
patients during the study follow-up, whether they received HBT or not. Eight of these patients 
(11.6%) experienced bleeding (cf table1). All of them were considered to be at high risk of 
thrombo-embolism according to the CHA(2)DS(2)-VASc
4 
score and at low-risk of bleeding 
according to the HAS-BLED bleeding risk score
4  .
Bleeding was severe in 5 patients (7.2%), 
with one related death. These severe bleedings occurred in the first 4 days and were always 
associated to HBT: in 3 cases, an heparin over-dosage was observed despite a correct heparin 
initial dose, in 1 case the INR was above the target range simultaneously to intercurrent 
infectious disease and the last occurred in a patient with a triple antithrombotic therapy and a 
very unstable health status. No thrombopenia was observed in the patients with a bleeding 
event.  
DISCUSSION 
This study showed a high rate (85.5%) of HBT use in octogenarians with AF starting 
VKA in acute-care units. The rate of bleeding events occurring in these patients during the 
first week of the fluindione initiation was very high (11.6%), especially the rate of severe 
bleeding (7.2%).  
Inception cohorts
5,6 
have established that bleeding risk is increased in AF octogenarians 
(especially in the first 90 days). The incidence of bleedings ranges from 1.9 to 13.1/100 
person-years, but this estimate is subject to selection and methodological biases
7,8
. These 
cohorts included outpatients or mixed populations, the VKA (warfarin) was managed by 
anticoagulation clinics and the rate of heparin bridging therapy was not specified. The rate of 
bleeding in our small cohort is particularly worrying. It may be explained by the studied 
population (very old patients with unstable clinical status) with VKA (fluindione) managed by 
hospital clinicians without algorithm. The high rate of HBT may also have contributed to 
these bleedings, at least in 3 patients with an anti-Xa activity above the upper therapeutic 
range. However, heparin was not contra indicated in our population, according to the scores 
assessing risks of bleedings and of thrombotic events (cf table 1).It is surprising that the HAS-
BLED score, which has the best predictive value of several bleeding risk stratification 
schemas
9
, concluded wrongly to a low risk for bleeding (maximum risk of 1.88 bleeds per 100 
patient years) in our patients with bleeding.  The retrospective assessment of the score may 
have underestimated some items, notably alcohol use and labile INR. Above all, this score, 
which is based on almost 4,000 out and inpatients in the EuroHeart Survey on AF (mean Age 
66+/-13 years) followed during one year for major bleeding, probably does not adapt well to 
octogenarian inpatients starting anticoagulation.  
 
Our study has important limits due to its ancillary feature. First, the number and 
characteristics of the eligible non included patients were not recorded, precluding assessment 
of the sample representativity. Second, the high attrition rate could have induced an 
underestimation of bleeding and thrombotic events, especially those occurring after discharge. 
Nevertheless, our study underlines (i) the inappropriateness of the HAS-BLED score to 
predict individual risk of bleeding in octogenarian inpatients so that “known risk factors for 
increased risk of bleeding should be taken into account on an individual basis when starting 
anticoagulation”11 and (ii) the need for future well-designed studies to provide relevant 
evidence to make recommendations for HBT administration in octogenarians inpatients with 
AF. 
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*items of  CHA2DS2VASc score : ‘major’ risk factors weigthed two points are “Previous stroke/ transient ischaemic attack.or systemic embolism” and “Age > 75 years”, 
Clinically relevant non-major’ risk factors weighted one point are : “Heart failure or moderate to severe Left Ventricular  systolic dysfunction (e.g. < 40%)” and 
“Hypertension” and” Diabetes mellitus” and “Female sex” and “ Age 65–74 years” and “Vascular disease” 
† 
items of HAS-BLED score
 
:Hypertension defined as systolic blood pressure >160 mmHg (1 point), presence of chronic dialysis or renal transplantation or serum creatinine 
≥200 µmol/L (1 point), Abnormal liver function defined by chronic hepatic disease (e.g. cirrhosis) or biochemical evidence of significant hepatic derangement (e.g. bilirubin 
Type of AF 
and  
AF-related  
symptoms 
(EHRA score)4 
Age Sex Surgery CHA2DS2VASc score 
and risk stratification* 
 
 
HAS-BLED 
bleeding risk 
scoreand risk 
stratification
† 
 
Type of  
bleeding 
event 
a) VKA stop 
b) additionnal  
treatment 
c) additional 
 investigations 
 
Date of 
bleeding 
†† 
 
INR> 3
§ HBT AntiXa   
or PTT  
> therapeutic  
target 
§ 
Comments 
First diagnosed AF 
Dyspnea 
(EHRA 4) 
83 M No 4 = High risk 2= low risk Abdominal 
wall 
haematoma 
(9X6cm) 
with anemia 
(7.8g/dl)) 
a) Yes  
b) Blood  
transfusion 
+ Vitamin K 
c) Abdominal 
 echography 
D4 
 
Yes 
3,37 
Yes 
LMWH 
No Infectious event with prescription of  
Telithromycin  respectively at D0 and 
D1 
Fluindione dose was decreased from 15 
to 10mg at D2 
 
First diagnosed AF 
Dyspnea 
(EHRA 4) 
88 M No 4 = High risk  2= low risk Hemorrhagic 
shock on 
digestive 
hemorrhage  
with anemia 
(5 g/dl)  
a) Yes 
b) Blood  
transfusion  
 + Gelofusine 
c) UGE 
D2 
 
No 
1.45 
Yes 
LMWH  
No Severe infectious disease before 
fluindione start with   increased CRP 
(68), low serum albumin (28g/l) and 
prescription of Lévofloxacine (D-10 to 
D0) and amoxicillin  clavulanic acid ( 
D-8 to D0).  
Aspirin was stopped at D-1 
Permanent AF 
No symptom  
(EHRA 1) 
85 M No 4 = High risk  2= low risk Psoas 
Haematoma 
a) Yes 
b) No 
c) TDM 
D4 No 
1.45 
Yes 
UFH 
Yes Initial dose  of HBT adjusted to  
clearance  
and weight ( moderate renal failure at 
admission) 
No acute failure during the stay 
First diagnosed AF 
Dyspnea 
(EHRA 4) 
88 F No 4 = High risk 2= low risk Ankle 
haematoma  
a) Yes 
b) Yes 
c) No 
D3 No 
1.44 
Yes 
Calcium  
heparin 
Yes 
First diagnosed AF 
No symptom  
(EHRA 1) 
85 F No 4 = High risk 1= low risk Hemorrhagic 
shock with 
death   
a) Yes 
b) Yes 
c) No 
D2 
 
No 
1.39 
Yes 
LMWH 
Yes Documented acute renal failure at D3 
(no renal failure at admission) 
First diagnosed AF 
Dyspnea  
(EHRA 3) 
92 F No 4 = High risk 2= low risk Epistaxis a) No 
b) No 
c) No 
D6  No 
2.68 
Yes 
LMWH 
No Documented acute renal failure at D4 
(moderate renal failure at admission) 
Persistent AF  
No symptom 
(EHRA 1) 
82 F Yes:  
Aortic valve  
remplacement 
5= High risk 2= low risk Rectum 
haemorrhage 
a) No 
b) No 
c) No 
D8 No 
2.61 
No NA  
Paroxysmal AF 
>48h 
feeling of faintness  
(EHRA 4) 
83 F No 3 = High risk 1= low risk Rectum 
haemorrhage 
a) No 
b) No 
c) No 
D3 No 
2.82 
No NA  
  
Table 1: Bleeding events during PREPA study (severe bleedings in grey)   
Table 1 : Bleeding events during the PREPA study (severe bleedings in grey) 
.2 x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase .3 x upper limit normal, etc. (one point), stroke (one 
point), previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anaemia,(one point) labile INRs (one point- this item was systematically weighted 
zero in our study), age>65 years (one point), concomitant use of drug (antithrombotic agents, non-steroidal anti-inflammatory drugs etc) (one point) or alcohol (one point ) 
†
 
†
 D0=Day of  fluindione initiation 
§
the day of the bleeding event  
AF= Atrial Fibrillation ; CRP= C-Reactive Protein ; EHRA =European Heart Rhythm Association ; HBT= Heparin Bridging Therapy ; HTA = Hypertension ;  LMWH=Low-
Molecule-Weight Heparin ; NA = Non adapted item ; PTT= Partial Thromboplastin Time ; TDM= Tomodensitometry ; UGE= Upper Gastrointestinal Endoscopy ; UFH= 
Unfractionned Heparin ; VKA= Vitamin K antagonist 
 
 
